Vitaprost Plus, 10 pcs., rectal suppositories
Vitaprost®
Vitaprost® forte
Has an organotropic effect on the prostate gland. Reduces the degree of edema, leukocyte infiltration of the prostate gland, normalizes the secretory function of epithelial cells, increases the number of lecithin grains in the secretion of the acini, stimulates the muscle tone of the bladder. Improves microcirculation in the prostate gland by reducing thrombus formation, antiplatelet activity, and prevents the development of venule thrombosis in the prostate gland.
Vitaprost® and Vitaprost® forte help normalize the parameters of the prostate gland and ejaculate. Reduce pain and discomfort, eliminate dysuric phenomena, improve copulatory function.
Based on clinical research data, it has been proven that Vitaprost® tablets and Vitaprost® forte moderately reduce the volume of the prostate gland. The drugs reduce the severity of obstructive and irritative symptoms in benign prostatic hyperplasia, which is expressed in an increase in the maximum and average volumetric flow rates of urine and a decrease in the volume of residual urine.
Data from clinical studies have proven that the use of Vitaprost® tablets reduces the likelihood of developing exacerbations of chronic abacterial prostatitis, does not cause changes in clinical and biochemical blood tests, and general urinalysis. The effectiveness of using Vitaprost® tablets for the prevention of exacerbations of chronic abacterial prostatitis, according to medical researchers, is 97.5%.
Vitaprost® forte improves blood microcirculation in the wall of the bladder due to the expansion of intact vessels (vasodilation effect), thereby helping to restore oxygen delivery to tissues experiencing hypoxia, which stimulates physiological repair. It has an anti-inflammatory effect by improving trophic processes in the bladder wall and stimulating regenerative processes. Activation of organ blood flow helps to improve the adaptive and contractile activity of the detrusor, increasing the capacity of the bladder.
A decrease in detrusor ischemia can explain the marked decrease in bladder hyperactivity, which continues after the end of Vitaprost® forte use.
Vitaprost® Plus
The combined drug Vitaprost® Plus has antimicrobial and anti-inflammatory properties.
Lomefloxacin is a broad-spectrum bactericidal agent from the group of fluoroquinolones. It affects the bacterial enzyme DNA gyrase, which ensures supercoiling, forms a complex with its tetramer (A2B2 gyrase subunits) and disrupts the transcription and replication of DNA, leading to the death of the microbial cell. Highly active against gram-negative aerobic microorganisms: Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli, Citrobacter diversus, Klebsiella pneumoniae, Enterobacter cloacae, Proteus vulgaris, Salmonella spp., Shigella spp., Moraxella morganii, Haemophilus influenzae et parainfluenzae, Legionella pneumophila, Pseudomonas aer uginosa .
Moderately sensitive to the drug -
Staphylococcus aureus, Staphylococcus epidermidis, Serratia liquefaciens, Serratia marcescens, Mycobacterium tuberculosis, Chlamydia trachomatis, Hafnia alvei, Citrobacter freundii, Aeromonas hydrophila, Proteus mirabilis, Proteus stuartii, Providencia rettgeri, Providencia alcalifaciens, Kle bsiella oxytoca, Klebsiella ozaenae, Enterobacter aerogenes, Enterobacter agglomerans.
Resistant to the drug are
Streptococcus spp., Pseudomonas cepacia, Ureaplasma urealyticum, Treponema pallidum, Mycoplasma hominis
and anaerobic bacteria. It acts on most microorganisms in low concentrations (the concentration required to inhibit the growth of 90% of strains, usually no more than 1 μg/ml). Resistance rarely develops.
Prostate extract reduces the degree of edema and leukocyte infiltration of the prostate gland, normalizes the secretory function of epithelial cells, increases the number of lecithin grains in the acini secretion, and stimulates the muscle tone of the bladder. Reduces thrombus formation, has antiplatelet activity, and prevents the development of venule thrombosis in the prostate gland. Normalizes prostate and ejaculate parameters. Reduces pain and discomfort, improves copulatory function.
Vitaprost plus Suppositories, 10 pcs, 400+20 mg+mg, rectal, for adults
special instructions
Special instructions when using the drug Vitaprost Plus are associated with the presence in its composition of the antibiotic lomefloxacin, which belongs to the group of fluoroquinolones.
During treatment with Vitaprost Plus, the simultaneous use of antimicrobial agents—fluoroquinolones—should be limited in order to avoid the development of an overdose and an increase in the frequency of side effects.
In case of cirrhosis of the liver, no adjustment of the dosage regimen is required (provided that renal function is normal).
During the treatment period, prolonged exposure to sunlight and the use of artificial ultraviolet lighting should be avoided. At the first signs of photosensitivity (increased skin sensitivity, burns, hyperemia, swelling, the appearance of blisters, rashes, itching, dermatitis), hypersensitivity, manifestations of neurotoxicity (excitement, convulsions, tremors, photophobia, confusion, toxic psychoses, hallucinations), therapy should be stopped.
Used only for the treatment of adult men; not used in women and children.
Treatment of chronic prostatitis should be comprehensive, involving, along with the prescription of the drug Vitaprost Plus, the use of other groups of medications and non-drug treatment methods.
Before starting treatment for chronic prostatitis and, if necessary, during treatment, it is recommended to analyze prostate secretions.
During treatment with Vitaprost Plus, there is a potential risk of developing hypoglycemia, including the development of hypoglycemic coma, which is more common in older people and patients with diabetes mellitus who take oral hypoglycemic drugs or insulin. Therefore, plasma glucose concentrations should be carefully monitored in these patients.
At the first signs of hypoglycemia (confusion, dizziness, ravenous appetite, headache, nervousness, palpitations or increased pulse rate, pale skin, perspiration, trembling, weakness), therapy should be stopped.
During treatment with Vitaprost Plus, there is a risk of developing mental adverse reactions that may appear even after a single dose.
Treatment with Vitaprost Plus should be stopped immediately if the patient reports any central nervous system side effects, including mental disturbances, or decreased glucose concentrations, and treatment with an antibiotic other than a fluoroquinolone should be immediately initiated if possible.
Epidemiological studies have reported an increased risk of aortic aneurysm and dissection after use of fluoroquinolones, especially in elderly patients.
In patients with a history of aneurysm, or who have aortic aneurysm and/or dissection, and other risk factors or conditions predisposing to the development of aortic aneurysm and dissection (eg, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, arterial hypertension, atherosclerosis), fluoroquinolones should be used only after a careful assessment of the benefit-risk ratio and consideration of other possible treatment options.
If patients experience sudden pain in the abdomen, chest, or back, they should contact their doctor immediately at the emergency room.
Vitaprost Plus
Vitaprost Plus supp rect 400 mg+20 mg x10,
ATX code: G04BX (Other drugs for the treatment of urological diseases)
Dosage form
Vitaprost® Plus
Supp. rectal: 5 or 10 pcs.reg. No.: LSR-002821/07 dated 09/20/07 - Indefinitely Re-registration date: 08/25/16
Release form, packaging and composition of Vitaprost® Plus
Rectal suppositories are from white or almost white to light cream with a grayish tint, torpedo-shaped, a white coating may appear on the surface of the suppository.
1 sup.
prostate extract 100 mg,
in terms of water-soluble peptides 20 mg
lomefloxacin hydrochloride 400 mg
Excipients: solid fat (vitepsol (brands H15, W35), supposir (brands NA15, NAS50)) - until a suppository weighing 2.25 g is obtained.
5 pieces. — cellular contour packages (1) — cardboard packs. 5 pieces. — contour cell packaging (2) — cardboard packs.
Clinical-pharmacological group: A drug with antibacterial and anti-inflammatory action, used for diseases of the prostate gland Pharmaco-therapeutic group: A drug for the treatment of chronic prostatitis
pharmachologic effect
A combined drug with antibacterial and anti-inflammatory effects, used for prostate diseases.
Lomefloxacin is a broad-spectrum bactericidal agent from the group of fluoroquinolones. It affects the bacterial enzyme DNA gyrase, which ensures DNA supercoiling, forms a complex with its tetramer (A2B2 gyrase subunits) and disrupts the transcription and replication of DNA, leading to the death of the microbial cell.
Highly active against gram-negative aerobic microorganisms: Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli, Citrobacter diversus, Klebsiella pneumoniae, Enterobacter cloacae, Proteus vulgaris, Salmonella spp., Shigella spp., Moraxella morganii, Haemophilus influenzae, Haemophilus parainfluenzae, Pseudomonas aeruginosa, Leg ionella pneumophila.
Moderately sensitive to the drug Staphylococcus aureus, Staphylococcus epidermidis, Serratia liquifaciens, Serratia marcescens, Mycobacterium tuberculosis, Chlamydia trachomatis, Hafnia alvei, Citrobacter freundii, Aeromonas hydrophila, Proteus mirabilis, Proteus stuartii, Providencia rettgeri, Providencia alcalifaciens, Kle bsiella oxytoca, Klebsiella ozaenae, Enterobacter aerogenes, Enterobacter agglomerans.
Streptococcus spp., Pseudomonas cepacia, Ureaplasma urealyticum, Treponema pallidum, Mycoplasma hominis and anaerobic bacteria are resistant to the drug.
Lomefloxacin acts on most microorganisms in low concentrations (the concentration required to inhibit the growth of 90% of strains, usually no more than 1 μg/ml). Resistance rarely develops.
Prostate extract has an organotropic effect on the prostate. Reduces the degree of edema, leukocyte infiltration of the prostate gland, normalizes the secretory function of epithelial cells, increases the number of lecithin grains in the secretion of the acini, stimulates the muscle tone of the bladder. Reduces thrombus formation, has antiplatelet activity, and prevents the development of venule thrombosis in the prostate gland. Normalizes prostate and ejaculate parameters. Reduces pain and discomfort, improves copulatory function.
Pharmacokinetics Data on the pharmacokinetics of Vitaprost® Plus are not provided.
Indications for Vitaprost® Plus
acute and chronic bacterial prostatitis caused by sensitive microorganisms (including those accompanied by inflammatory diseases of the genitourinary tract), conditions before and after surgery on the prostate gland. ICD-10 codes
Dosage regimen
The drug should be used rectally, 1 suppository 1 time/day after an enema or spontaneous bowel movement.
Before use, the suppository should be removed from the blister pack. After administration of the drug, the patient should remain in bed for 30-40 minutes.
The course of treatment continues until the pathogen disappears in the prostate secretion and ranges from 10 to 30 days (individually for each patient).
Side effect
Side effects of the drug Vitaprost® Plus, with the exception of allergic reactions, are associated with the presence of the antibiotic lomefloxacin in its composition.
Allergic reactions: skin itching, urticaria, photosensitivity, malignant exudative erythema (Stevens-Johnson syndrome).
From the nervous system: asthenia, dizziness, nervousness, anxiety, fatigue, malaise, headache, fainting, insomnia, hallucinations, convulsions, hyperkinesis, tremor, paresthesia, depression, agitation.
From the digestive system: pseudomembranous enterocolitis, dysbacteriosis, dryness of the oral mucosa, diarrhea or constipation, flatulence, discoloration of the tongue, decreased appetite or bulimia, perversion of taste, increased activity of liver transaminases.
From the hematopoietic organs and hemostasis system: bleeding from the gastrointestinal tract, thrombocytopenia, increased fibrinolysis, lymphadenopathy, purpura, nosebleeds.
From the cardiovascular system: decreased blood pressure, tachycardia, bradycardia, extrasystole, arrhythmias, progression of heart failure and angina, pulmonary embolism, cardiomyopathy, phlebitis.
From the urinary system: glomerulonephritis, dysuria, polyuria, anuria, albuminuria, urethral bleeding, crystalluria, hematuria, urinary retention, edema.
From the reproductive system: orchitis, epididymitis.
Metabolism: hypoglycemia, gout.
From the musculoskeletal system: arthralgia, vasculitis, calf muscle cramps, back and chest pain.
From the respiratory system: shortness of breath, bronchospasm, cough, hypersecretion of sputum, flu-like symptoms.
From the senses: blurred vision, pain and noise in the ears, pain in the eyes.
Other: increased sweating, chills, thirst, superinfection.
Contraindications for use
childhood and adolescence up to 18 years of age (the period of formation and growth of the skeleton), increased sensitivity to the components of the drug.
The drug should be used with caution in cerebral atherosclerosis, epilepsy and other diseases of the central nervous system with epileptic syndrome.
Use during pregnancy and breastfeeding The drug is not used in women.
Use for liver dysfunction In case of liver cirrhosis, no dosage adjustment is required (provided normal renal function).
Use in children Contraindication: childhood and adolescence under 18 years of age (the period of skeletal formation and growth).
special instructions
During treatment with Vitaprost® Plus, the simultaneous use of antimicrobial agents - fluoroquinolones should be limited in order to avoid the development of overdose and an increase in the frequency of side effects.
In case of cirrhosis of the liver, no adjustment of the dosage regimen is required (provided that renal function is normal).
During the treatment period, prolonged exposure to sunlight and the use of artificial UV lighting should be avoided. At the first signs of photosensitivity (including increased skin sensitivity, burns, hyperemia, swelling, blistering, rash, itching, dermatitis), hypersensitivity, manifestations of neurotoxicity (including agitation, convulsions, tremor, photophobia, confusion , toxic psychoses, hallucinations) therapy should be discontinued.
Impact on the ability to drive vehicles and operate machinery
During the treatment period, patients must be careful when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Overdose Data on drug overdose are not provided.
Drug interactions
With simultaneous use, the activity of oral anticoagulants increases and the toxicity of NSAIDs increases.
Drugs that block tubular secretion slow down the elimination of the drug.
There is no cross-resistance with penicillins, cephalosporins, aminoglycosides, co-trimoxazole, metronidazole.
Storage conditions for Vitaprost® Plus
The drug should be stored out of the reach of children at a temperature not exceeding 20°C.
Shelf life of Vitaprost® Plus Shelf life - 2 years.
Conditions of sale According to a doctor's prescription.
